Law360, New York (April 23, 2010, 6:27 PM ET) -- Pay-for-delay settlements between name-brand drugmakers and their generics rivals are still a major target for the Federal Trade Commission's competition enforcers, the agency said Friday in its annual report.
FTC Chairman Jon Leibowitz named pay-for-delays a “top priority” in the report, a comprehensive look at the past fiscal year for the commission.
“We will press to eliminate anti-competitive pay-for-delay patent settlements that deprive consumers of low-cost drugs,” the FTC said in a forward-looking section of the report, after singling out the settlements as "unconscionable" in the...
Pay-For-Delay Deals Remain In FTC's Crosshairs
To view the full article, take a free trial now.
